Search research articles
Contact Us
Filters
Showing results (131-140 of 170) with videos related to
Page
of 17
Sort By:
JAMA Network Open
|
March 20, 2025
Treatment and Attrition Trends for Metastatic Clear Cell Renal Cell Carcinoma in the US
Zeynep Irem Ozay, Yeonjung Jo, Gliceida Galarza Fortuna, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 4, 2025
Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate Cancer
Nicolas Sayegh, Ryon P Graf, Umang Swami, et al.
JAMA Network Open
|
June 24, 2026
Bone-Modifying Agents in Metastatic Castration-Resistant Prostate Cancer
Zeynep Irem Ozay, Yeonjung Jo, Georges Gebrael, et al.
Cancer
|
April 2, 2024
Cabozantinib with immune checkpoint inhibitor versus cabozantinib monotherapy in patients with metastatic clear cell renal cell carcinoma progressing after prior immune checkpoint inhibitor
Georges Gebrael, Yeonjung Jo, Vinay Mathew Thomas, et al.
European Urology Focus
|
April 5, 2024
Impact of Synchronous versus Metachronous Metastasis on Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated with First-line Immune Checkpoint Inhibitor-based Combinations
Georges Gebrael, Luis Meza, Xiaochen Li, et al.
JAMA Network Open
|
June 29, 2026
Treatment Patterns and Attrition in Metastatic Castration-Resistant Prostate Cancer
Gabriel Hooper, Yeonjung Jo, Varun Nandakumar, et al.
JAMA Network Open
|
April 7, 2026
Trends and Disparities in the Use of Next-Generation Sequencing in Patients With Cancer in the United States
Chadi Hage Chehade, Zeynep Irem Ozay, Yeonjung Jo, et al.
JAMA Network Open
|
October 2, 2025
Receipt of PARP Inhibitors in Patients With Metastatic Prostate Cancer Harboring BRCA1/2 Alterations
Micah Ostrowski, Yeonjung Jo, Chadi Hage Chehade, et al.
The Journal of Urology
|
July 26, 2024
Early Prostate-Specific Antigen Response by 6 Months Is Predictive of Treatment Effect in Metastatic Hormone Sensitive Prostate Cancer: An Exploratory Analysis of the TITAN Trial
Soumyajit Roy, Yilun Sun, Kim N Chi, et al.
JCO Oncology Practice
|
May 29, 2026
Development and External Validation of a Machine Learning-Based Risk Classification Score for Prostate Cancer-Specific Cardiovascular Risk
Nickolas Stabellini, Tarek Nahle, Viraj Shah, et al.
Page
of 17
Search research articles
Search
Showing results (131-140 of 170) with videos related to
Sort By:
Page
of 17
JAMA Network Open
|
March 20, 2025
Treatment and Attrition Trends for Metastatic Clear Cell Renal Cell Carcinoma in the US
Zeynep Irem Ozay, Yeonjung Jo, Gliceida Galarza Fortuna, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 4, 2025
Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate Cancer
Nicolas Sayegh, Ryon P Graf, Umang Swami, et al.
JAMA Network Open
|
June 24, 2026
Bone-Modifying Agents in Metastatic Castration-Resistant Prostate Cancer
Zeynep Irem Ozay, Yeonjung Jo, Georges Gebrael, et al.
Cancer
|
April 2, 2024
Cabozantinib with immune checkpoint inhibitor versus cabozantinib monotherapy in patients with metastatic clear cell renal cell carcinoma progressing after prior immune checkpoint inhibitor
Georges Gebrael, Yeonjung Jo, Vinay Mathew Thomas, et al.
European Urology Focus
|
April 5, 2024
Impact of Synchronous versus Metachronous Metastasis on Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated with First-line Immune Checkpoint Inhibitor-based Combinations
Georges Gebrael, Luis Meza, Xiaochen Li, et al.
JAMA Network Open
|
June 29, 2026
Treatment Patterns and Attrition in Metastatic Castration-Resistant Prostate Cancer
Gabriel Hooper, Yeonjung Jo, Varun Nandakumar, et al.
JAMA Network Open
|
April 7, 2026
Trends and Disparities in the Use of Next-Generation Sequencing in Patients With Cancer in the United States
Chadi Hage Chehade, Zeynep Irem Ozay, Yeonjung Jo, et al.
JAMA Network Open
|
October 2, 2025
Receipt of PARP Inhibitors in Patients With Metastatic Prostate Cancer Harboring BRCA1/2 Alterations
Micah Ostrowski, Yeonjung Jo, Chadi Hage Chehade, et al.
The Journal of Urology
|
July 26, 2024
Early Prostate-Specific Antigen Response by 6 Months Is Predictive of Treatment Effect in Metastatic Hormone Sensitive Prostate Cancer: An Exploratory Analysis of the TITAN Trial
Soumyajit Roy, Yilun Sun, Kim N Chi, et al.
JCO Oncology Practice
|
May 29, 2026
Development and External Validation of a Machine Learning-Based Risk Classification Score for Prostate Cancer-Specific Cardiovascular Risk
Nickolas Stabellini, Tarek Nahle, Viraj Shah, et al.
Page
of 17